Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Oncology Biosimilars Market by Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF , Others), By Application (Retail Pharmacies, Hospital Pharmacy, Online Pharmacy) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Oncology Biosimilars Market by Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF , Others), By Application (Retail Pharmacies, Hospital Pharmacy, Online Pharmacy) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 204437 3300 Pharma & Healthcare 377 248 Pages 4.9 (33)
                                          

The global oncology biosimilars market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of cancer cases and the rising demand for cost-effective treatment options. The global oncology biosimilars market by type includes mAb, immunomodulators, hematopoietic agents, and CSF. The mAb segment accounted for the largest share in 2018 due to its high adoption rate in various therapeutic areas such as breast cancer, lung cancer, and prostate cancer. Immunomodulators are expected to witness significant growth during the forecast period owing to their use in various types of cancers such as leukemia and lymphoma. Hematopoietic agents are also anticipated to grow at a significant pace due to their use in treating blood disorders such as anemia or leukemia. CSF is anticipated to witness moderate growth during the forecast period owing its use in treating brain tumors or spinal cord injuries among others   Â. The global oncology biosimilars market by application includes retail pharmacies, hospital pharmacy, and online pharmacy segments. The retail pharmacies segment accounted for the largest share in 2018 due its wide availability across different geographies which makes it more accessible than other segments like hospital pharmacy or online pharmacy segments which are limited only within specific geographies  Â.

Some Of The Growth Factors Of This Market:

  1. Increasing prevalence of cancer and rising healthcare expenditure are the major factors driving the growth of this market.
  2. Increasing number of approvals for biosimilar drugs by regulatory authorities is also expected to fuel the growth of this market in near future.
  3. Lack of awareness about biosimilars among physicians and patients, high cost associated with these drugs, and lack of reimbursement policies are some factors that may hinder the growth rate in near future.
  4. The global Oncology Biosimilars market is segmented on basis of product type, end user, region, and country.

Industry Growth Insights published a new data on “Oncology Biosimilars Market”. The research report is titled “Oncology Biosimilars Market research by Types (mAb, Immunomodulators, Hematopoietic Agents, G-CSF , Others), By Applications (Retail Pharmacies, Hospital Pharmacy, Online Pharmacy), By Players/Companies Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Oncology Biosimilars Market Research Report

By Type

mAb, Immunomodulators, Hematopoietic Agents, G-CSF , Others

By Application

Retail Pharmacies, Hospital Pharmacy, Online Pharmacy

By Companies

Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

248

Number of Tables & Figures

174

Customization Available

Yes, the report can be customized as per your need.


Global Oncology Biosimilars Industry Outlook


Global Oncology Biosimilars Market Report Segments:

The global Oncology Biosimilars market is segmented on the basis of:

Types

mAb, Immunomodulators, Hematopoietic Agents, G-CSF , Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Retail Pharmacies, Hospital Pharmacy, Online Pharmacy

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Celltrion
  2. Biocon
  3. Dr. Reddy’s Laboratories
  4. STADA Arzneimittel AG
  5. Intas Pharmaceuticals
  6. Pfizer
  7. Sandoz International
  8. Teva Pharmaceutical Industries Ltd
  9. Apotex
  10. BIOCAD

Global Oncology Biosimilars Market Overview


Highlights of The Oncology Biosimilars Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. mAb
    2. Immunomodulators
    3. Hematopoietic Agents
    4. G-CSF 
    5. Others
  1. By Application:

    1. Retail Pharmacies
    2. Hospital Pharmacy
    3. Online Pharmacy
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Oncology Biosimilars Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Oncology Biosimilars Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Oncology biosimilars are medications that are made to duplicate the action of a particular type of cancer medication. These medications can help patients with cancer fight their disease more effectively by providing them with a new and improved treatment option.

Some of the major players in the oncology biosimilars market are Celltrion, Biocon, Dr. Reddy¢â‚¬â„¢s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD.

The oncology biosimilars market is expected to register a CAGR of 16.2%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Oncology Biosimilars Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Oncology Biosimilars Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Oncology Biosimilars Market - Supply Chain
   4.5. Global Oncology Biosimilars Market Forecast
      4.5.1. Oncology Biosimilars Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Oncology Biosimilars Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Oncology Biosimilars Market Absolute $ Opportunity

5. Global Oncology Biosimilars Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Oncology Biosimilars Market Size and Volume Forecast by Type
      5.3.1. mAb
      5.3.2. Immunomodulators
      5.3.3. Hematopoietic Agents
      5.3.4. G-CSF 
      5.3.5. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Oncology Biosimilars Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Oncology Biosimilars Market Size and Volume Forecast by Application
      6.3.1. Retail Pharmacies
      6.3.2. Hospital Pharmacy
      6.3.3. Online Pharmacy
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Oncology Biosimilars Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Oncology Biosimilars Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Oncology Biosimilars Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Oncology Biosimilars Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Oncology Biosimilars Demand Share Forecast, 2019-2026

9. North America Oncology Biosimilars Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Oncology Biosimilars Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Oncology Biosimilars Market Size and Volume Forecast by Application
      9.4.1. Retail Pharmacies
      9.4.2. Hospital Pharmacy
      9.4.3. Online Pharmacy
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Oncology Biosimilars Market Size and Volume Forecast by Type
      9.7.1. mAb
      9.7.2. Immunomodulators
      9.7.3. Hematopoietic Agents
      9.7.4. G-CSF 
      9.7.5. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Oncology Biosimilars Demand Share Forecast, 2019-2026

10. Latin America Oncology Biosimilars Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Oncology Biosimilars Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Oncology Biosimilars Market Size and Volume Forecast by Application
      10.4.1. Retail Pharmacies
      10.4.2. Hospital Pharmacy
      10.4.3. Online Pharmacy
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Oncology Biosimilars Market Size and Volume Forecast by Type
      10.7.1. mAb
      10.7.2. Immunomodulators
      10.7.3. Hematopoietic Agents
      10.7.4. G-CSF 
      10.7.5. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Oncology Biosimilars Demand Share Forecast, 2019-2026

11. Europe Oncology Biosimilars Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Oncology Biosimilars Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Oncology Biosimilars Market Size and Volume Forecast by Application
      11.4.1. Retail Pharmacies
      11.4.2. Hospital Pharmacy
      11.4.3. Online Pharmacy
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Oncology Biosimilars Market Size and Volume Forecast by Type
      11.7.1. mAb
      11.7.2. Immunomodulators
      11.7.3. Hematopoietic Agents
      11.7.4. G-CSF 
      11.7.5. Others
   11.8. Basis Point Share (BPS) Analysi by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Oncology Biosimilars Demand Share, 2019-2026

12. Asia Pacific Oncology Biosimilars Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Oncology Biosimilars Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Oncology Biosimilars Market Size and Volume Forecast by Application
      12.4.1. Retail Pharmacies
      12.4.2. Hospital Pharmacy
      12.4.3. Online Pharmacy
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Oncology Biosimilars Market Size and Volume Forecast by Type
      12.7.1. mAb
      12.7.2. Immunomodulators
      12.7.3. Hematopoietic Agents
      12.7.4. G-CSF 
      12.7.5. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Oncology Biosimilars Demand Share, 2019-2026

13. Middle East & Africa Oncology Biosimilars Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Oncology Biosimilars Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Oncology Biosimilars Market Size and Volume Forecast by Application
      13.4.1. Retail Pharmacies
      13.4.2. Hospital Pharmacy
      13.4.3. Online Pharmacy
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Oncology Biosimilars Market Size and Volume Forecast by Type
      13.7.1. mAb
      13.7.2. Immunomodulators
      13.7.3. Hematopoietic Agents
      13.7.4. G-CSF 
      13.7.5. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Oncology Biosimilars Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Oncology Biosimilars Market: Market Share Analysis
   14.2. Oncology Biosimilars Distributors and Customers
   14.3. Oncology Biosimilars Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Celltrion
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Biocon
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Dr. Reddy’s Laboratories
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. STADA Arzneimittel AG
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Intas Pharmaceuticals
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Pfizer
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Sandoz International
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Teva Pharmaceutical Industries Ltd
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Apotex
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. BIOCAD
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us